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Abst ract
The authors present the case of a 19-year-old patient with 
Wilson disease (WD) who developed symptoms of acute focal
dystonia of the left hand (a ‘starfish’ hand presentation) short-
ly after treatment with the tricyclic antidepressant clo mi -
pramine. The diagnosis of WD was made 8 months earlier
based on abnormal copper metabolism parameters and was
confirmed by genetic testing. Initially, the patient presented
with akathisia, sialorrhea, oromandibular dystonia (occasio -
nally grimacing) and slight dysarthria. The patient’s symp-
toms diminished after treatment with d-penicillamine was 
initiated. No further deterioration was observed after copper-
chelating therapy was started.
The authors diagnosed acute focal dystonia induced by clo -
mipramine.
Botulinum toxin and intensive rehabilitation was initiated;
complete regression of hand dystonia was observed. Based
on the case, the authors suggest that care should be exercised
with regard to starting medications that could potentially
impact the extrapyramidal system in WD patients.
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CASE REPORT/OPIS PRZYPADKU
St reszc zenie
W pracy przedstawiono przypadek 19-letniego pacjenta
z cho rob¹ Wilsona, u którego po w³¹czeniu trójpierœcienio-
wego leku przeciwdepresyjnego – klomipraminy – wyst¹pi³y
objawy ostrej dystonii ogniskowej w postaci rêki „rozgwiaz-
dy”. Chorobê Wilsona rozpoznano u pacjenta 8 miesiêcy
wczeœniej na podstawie nieprawid³owego metabolizmu mie-
dzi i badañ genetycznych. Pocz¹tkowo chory prezentowa³
dyskretne objawy neurologiczne: akatyzjê, œlinotok, dysto-
niê ustno-¿uchwow¹ oraz dyzartriê. Po w³¹czeniu leczenia
d-pe ni cylamin¹ nie obserwowano pogorszenia stanu neuro-
logicznego, a pocz¹tkowe objawy w trakcie leczenia chela-
tuj¹cego znacznie siê zmniejszy³y, dlatego rozpoznano
u pacjenta ostr¹ dystoniê ogniskow¹ indukowan¹ klomipra-
min¹. Pacjenta leczono toksyn¹ botulinow¹ oraz rehabilito-
wano z dobrym efektem, objawy dystonii ogniskowej ca³ ko -
wicie ust¹pi³y w ci¹gu roku. Autorzy proponuj¹ zachowanie
szczególnej ostro¿noœci w stosowaniu leków potencjalnie
wp³ywaj¹cych na uk³ad pozapiramidowy u pacjentów z cho-
rob¹ Wilsona.
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Introduction
Wilson disease (WD) (OMIM 277900) is an inher-
ited autosomal recessive copper metabolism disorder
that results in copper accumulation in many organs
(brain, liver, cornea, kidney and heart) with secondary
damage of the affected tissues [1-4].
There is a wide spectrum of WD phenotypic pre-
sentation, including clinical signs and symptoms rang-
ing from predominantly asymptomatic hepatic presenta-
tion or asymptomatic increased level of ami notransferases
to acute liver failure, or to a predominantly neuropsy-
chiatric presentation, including various involuntary move-
ments and psychiatric symptoms [2,4-7]. At diagnosis,
up to 40% of WD patients present with neurological
symptoms, very often including multi-segmental or gen-
eral dystonia, which apart from tremor is the most fre-
quent and most severe presentation of WD [5]. Appro -
ximately 15% of WD patients present with psychiatric
manifestations [4,5]. These patients often require treat-
ment with antipsychotics or antidepressants. However,
due to damage within the dopaminergic system in pa -
tients with WD, such treatments should be used and
introduced very carefully due to the possibility of med-
ication-induced movement disorders (MIMDs) [8-12].
Medication-induced dystonia has been previously
described and, in most cases, is caused by drugs block-
ing the action of dopamine, especially those blocking D2
(dopamine) receptors in the caudate, putamen and glo -
bus pallidus [8-11]. The other drugs that cause dysto-
nia include pharmaceutics that change the balance
between serotonin and dopamine or between dopamine
and acetylcholine in the basal ganglia [13-21]. In the
literature, there are reports of acute dystonia produced
by (1) neuroleptics, (2) antiemetics, (3) antidepressants
such as tricyclic antidepressants (TCAs), monoamine
oxi dase inhibitors (MAOs), selective serotonin reup-
take inhibitors (SSRIs), serotonin antagonist and 
reupta ke inhibitors (SARIs), serotonin-norepinephrine
reuptake inhibitors (SNRIs), (4) antiepileptic drugs
(phe nytoin, carbamazepine, diazepam), and (5) antimi-
graine drugs (sumatriptan), among others [13-22]. In
patients with neurodegenerative disorders such as 
WD in whom symptoms of acute dystonia develop dur-
ing treatment, the following question should be consid-
ered: Are the symptoms related to the progression of 
the disease or to a movement disorder that is a side effect
of treatment?
We report the case of a patient with WD with slight
extrapyramidal syndrome (akathisia and oromandibu-
lar dystonia) in whom focal acute hand dystonia
occurred after treatment with the tricyclic antidepres-
sant clomipramine.
Case report
A 19-year-old patient was admitted to our depart-
ment of neurology in September 2005 because of acute
focal left hand dystonia with spreading of his fingers in
a ‘starfish’ pattern (Fig. 1). This symptom appeared in
July 2005 within 5 days of initiating clomipramine ther-
apy (20 mg/day) and then progressed to complete loss
of left hand function.
We first diagnosed the patient with Wilson disease
in January of 2005. The first clinical symptoms of WD
developed in March 2004 and included akathisia
(involuntary movements of both upper extremities),
sialorrhea and signs of dystonia, such as abnormal neck
posture, oromandibular dystonia with occasional face
grimacing and slight dysarthria (his speech was inaudi-
ble). At the time of diagnosis, no signs of left hand dys-
tonia were present. The diagnosis of WD was confir -
med by biochemical test results showing abnormal
cop per metabolism parameters: the serum ceruloplas-
min level was 0.009 g/L (normal: 0.092-0.164 g/L),
the serum copper was 5 µg/dL (normal: 70-140) and
the copper excretion in urine was 580 µg/24 h (normal: 
0-50). An ophthalmologic slit lamp examination re -
vealed the presence of Kayser-Fleischer rings bilater-
ally. Additionally, a brain MRI showed changes typical
of WD (Fig. 2). Finally, genetic testing revealed
homozygosity for the p.H1069Q mutation in both alle-
les of the ATP7B gene.
Beginning in January 2005, the patient was treated
with copper chelator d-penicillamine with a gradually
Fig. 1. Left hand dystonia with a ‘starfish’ presentation: acute phase
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increasing dose that started from 100 mg/day and
reached 1000 mg/day in February 2005.
In the summer of 2005, his parents observed
a decline in his mood. The consulting neurologist decid-
ed to introduce antidepressive treatment with clo mi -
pramine (20 mg/day). Five days later, the patient devel-
oped acute focal dystonia of the left hand.
The patient was seen again in our department.
A neurological examination at admission revealed severe
dystonia of the left hand with spreading of his fingers
in a ‘starfish’ configuration (the hand was not functio -
nal), hypomimia, and the continued presence of Kayser-
Fleischer rings in both eyes. Akathisia, sialorrhea, oro-
mandibular dystonia and dysarthria (observed at initial
diagnosis) and other clinical signs of WD were not pre-
sent.
We again measured copper metabolism parameters.
His urine demonstrated continued increased copper
excretion at a level of 676 µg/24 h (normal: 0-50),
which we attributed to good patient compliance with
d-penicillamine treatment. The overall clinical picture
suggested the occurrence of acute dystonia induced by
clomipramine. Because the dystonic symptoms per-
sisted for a relatively long time (3 months), we decid-
ed not to treat this patient with anticholinergic drugs.
We started with intensive rehabilitation and gave him
a series of injections with botulinum toxin (Dysport),
and complete recovery of the affected hand was
observed over the course of a one-year observation peri-
od (Fig. 3).
Discussion
We present this case as an example of an MIMD,
specifically a complication of treatment with the antide-
pressant clomipramine in a patient with WD.
In clinical practice, MIMDs can be divided into five
types [11]:
1) Acute focal dystonia, which starts rapidly within the
first 7 days (typically 96 hours) after medication treat-
ment (with antipsychotics, antidepressants and oth-
er drugs). Muscle spasms produce abnormal pos-
tures with pain. Fear and fever have also been
reported.
2) Tardive dyskinesia, which is the late onset of a neu-
roleptic-related movement disorder. This MIMD is
usually observed a few months or years after neu-
roleptic treatment. The symptoms include involun-
tary movements of mouth and face (very difficult to
treat).
3) Intermediate-onset types of movement, the symptoms
of which occur between 1 and 3 months after treat-
ment with medication that causes extrapyramidal
symptoms. Two forms of this MIMD may be dis-
tinguished: neuroleptic-induced parkinsonism (sym-
metrical signs) and akathisia (uncontrolled restless-
ness with compulsive movement of feet and fingers).
4) Neuroleptic malignant syndrome, which is a move-
ment disorder that can occur at any time. This dis-
order presents as coma, fever, high blood pressure,
or muscular rigidity.
Fig. 3. Complete recovery of the affected hand after one yearFig. 2. Brain MRI showing increased signal intensity on T2-weighted images
both in deep structures and in the thalamus
Tomasz Litwin, Grzegorz Chabik, Anna Cz³onkowska
Neurologia i Neurochirurgia Polska 2013; 47, 5 505
5) Tremor, which includes high-amplitude postural
tremor occurring after treatment with valproic acid,
lithium, amphetamine, or tricyclic antidepressants.
As mentioned in the introduction, most MIMDs
occur after neuroleptic use, but they can also occur dur-
ing treatment with other drugs that impact neuro-
transmitters in the basal ganglia. Antidepressant-
induced extrapyramidal symptoms are relatively rare
(incidence 1/1000), but failure to recognize these symp-
toms and their etiology could significantly impact
a patient’s quality of life [13]. The first recorded case
was described in 1959 as a coarse tremor after imi pra -
mine treatment [14]. The authors described this phe-
nomenon as a “manifestation of the dystonic type of
motor disturbance”. However, it has been reported that
different antidepressants elicit different extrapyramidal
symptoms or MIMDs [13-21]. Patients treated with
tricyclic antidepressant can present with dyskinesia,
akathisia, ‘rabbit syndrome’ and acute dystonia. These
adverse events are not frequent, are related to drug
dosage and could occur more often in patients with pre-
vious exposure to neuroleptics, lithium, or estrogens.
In patients treated with MAOs, there are reports of
akathisia, acute dystonia and parkinsonism. SARIs can
produce dystonia, parkinsonism, oculogyric crisis, tor-
ticollis and chorea, in addition to akathisia. Finally,
SSRIs can produce dystonic reactions, parkinsonism,
akathisia and tardive dyskinesia [13].
The mechanisms underlying the adverse effects of
antidepressants are not known, but changes in the bal-
ance between neurotransmitters such as serotonin and
dopamine or dopamine and acetylcholine in the basal
ganglia have been proposed. It is conceivable that these
drugs impact receptors in the brain, thereby modulating
dopaminergic functions. For example, TAC is a high-
affinity antagonist of serotoninergic (5-HT2, 5-HT6, 
5-HT7), adrenergic (α1-adrenergic), histaminergic (H1
and H2 receptors) and cholinergic receptors. SSRIs and
SARIs produce increased 5-hydroxytryptamine inhibi-
tion of nigrostriatal dopaminergic neurons [13].
The most common MIMD, which is particularly
common in younger patients, is acute focal dystonia,
especially in response to neuroleptics, but also, as men-
tioned above, in response to antidepressants and other
drugs [11]. The symptoms of acute focal dystonia usu-
ally start rapidly within the first 7 days (often within 
96 hours) after treatment initiation (with antipsychotics,
antidepressants and others). The muscle spasms pro-
duce abnormal postures with pain and occasionally fear
and fever.
In our patient, an MIMD (in the form of acute focal
dystonia of the left hand) was induced by clomipramine
treatment. Several risk factors for this type of adverse
drug reaction have been previously identified, including
male sex, young age (10-20 years old), use of cocaine,
and history of extrapyramidal syndrome [11,13]. In
patients with these risk factors, drug-induced dystonia
can be prevented by introducing anticholinergic therapy
(i.e., biperiden) during the first seven days of treatment
with potentially hazardous pharmaceuticals.
The treatment of acute dystonia induced by med-
ication is usually effective if it is initiated early [11,
16,20]. Intramuscular injections of anticholinergic drugs
resolve the symptoms in several minutes, and repeated
injections are usually not needed. Oral treatment with
anticholinergic drugs should be introduced and contin-
ued from 48 hours to 7 days to prevent recurrence of
the symptoms [11]. Treatment with the offending drug
should be discontinued. If dystonia persists in the patient
or if the symptoms persist or reoccur after a few months
(as they did in our patient), then treatment with botu-
linum toxin should be considered. In each case, the pos-
sibility of other underlying causes of dystonia should be
considered [11].
It should be noted that d-penicillamine can also
cause neurological deterioration in patients suffering
from WD, especially during the first months of treat-
ment [4-7,23]. These symptoms are caused by the rapid
release of copper from tissues into the blood, which pro-
duces a secondary increase in brain copper concentra-
tion and toxic brain damage [4-6].
Effective anti-copper treatment (as evidenced by high
copper excretion in the urine) as well as the recovery of
initial neurological signs and a lack of any new WD neu-
rological symptoms strongly confirmed that the dystonia
symptoms in this patient were closely related to clo -
mipramine treatment without prophylaxis with anti-
cholinergic drugs. The delay in neurological consultation
after the onset of dystonia contributed to the persistence
of the symptoms over a long period of time. Finally, treat-
ment with botulinum toxin and rehabilitation was effec-
tive and completely ameliorated the signs of dystonia.
In summary, we suggest that care should be exer-
cised when beginning any pharmacologic agent that
could produce EPS in WD patients due to the risk of
medication-induced movement disorders.
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